Modelling genetic and clinical heterogeneity in epithelial ovarian cancers

被引:30
作者
Lawrenson, Kate
Sproul, Duncan [2 ]
Grun, Barbara [1 ]
Notaridou, Maria [1 ]
Benjamin, Elizabeth [3 ]
Jacobs, Ian J. [1 ]
Dafou, Dimitra [1 ]
Sims, Andrew H. [2 ]
Gayther, Simon A. [1 ]
机构
[1] UCL, Gynaecol Canc Res Labs, UCL EGA Inst Womens Hlth, London WC1E 6DD, England
[2] Western Gen Hosp, Appl Bioinformat Canc Grp, Edinburgh Breakthrough Res Ctr, Inst Genet & Mol Med, Edinburgh EH4 2XR, Midlothian, Scotland
[3] UCL, Dept Histopathol, Inst Canc, London WC1E 6JJ, England
基金
英国医学研究理事会;
关键词
EXPRESSION PROFILES; BORDERLINE TUMORS; GROWTH-FACTOR; LOW-GRADE; C-MYC; MUTATIONS; CARCINOMA; CELLS; KRAS; TRANSFORMATION;
D O I
10.1093/carcin/bgr140
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The biology underlying early-stage epithelial ovarian cancer (EOC) development is poorly understood. Identifying biomarkers associated with early-stage disease could have a significant impact on reducing mortality. Here, we describe establishment of a three-dimensional (3D) in vitro genetic model of EOC initiation and early-stage neoplastic progression. Normal primary ovarian epithelial (POE) cells, immortalized using hTERT (immortalised ovarian epithelial [IOE] cells), were partially transformed by overexpressing the CMYC oncogene (IOECMYC cells). Subsequent expression of mutant alleles of KRAS (KRAS(G12V)) or BRAF (BRAF(V600E)) created double-mutant lines (IOECMYC.KRAS and IOECMYC.BRAF). The transformed phenotype of IOECMYC cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOECMYC cells had undergone morphological and phenotypic changes characteristic of neoplastic progression. When cultured as 3D spheroids, IOE cells underwent growth arrest, reminiscent of nonproliferative, unstimulated POE in vivo. In contrast, IOSECMYC+BRAF/KRAS cells formed highly proliferative, poly-aggregate spheroid structures, showing increased expression of the Wilms tumour 1 tumourigenic marker and MIB1 proliferation marker. Transcriptomic analyses identified different gene expression profiles between the different cell lines and novel candidate genes (e.g. RGS4, CTGF and THBS1) that are somatically altered in EOCs. Gene expression signatures were compared with signatures from primary EOCs; tumours with IOECMYC 'like' signatures were more likely to be high grade (P = 0.018); tumours with BRAF signatures were associated with improved relapse-free survival (P = 0.003). In conclusion, we have established in vitro 3D models of early-stage EOCs, which reflect genetic and phenotypic heterogeneity of the disease. Molecular genetic characteristics of these models correlated with molecular and clinical features of primary EOCs.
引用
收藏
页码:1540 / 1549
页数:10
相关论文
共 50 条
[21]   Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics [J].
Zhang, Meiying ;
Zhuang, Guanglei ;
Sun, Xiangjun ;
Shen, Yanying ;
Zhao, Aimin ;
Di, Wen .
JOURNAL OF OVARIAN RESEARCH, 2015, 8
[22]   The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review [J].
Lau, Chien-Hui ;
Seow, Kok-Min ;
Chen, Kuo-Hu .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
[23]   Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity [J].
Bodelon, Clara ;
Killian, J. Keith ;
Sampson, Joshua N. ;
Anderson, William F. ;
Matsuno, Rayna ;
Brinton, Louise A. ;
Lissowska, Jolanta ;
Anglesio, Michael S. ;
Bowtell, David D. L. ;
Doherty, Jennifer A. ;
Ramus, Susan J. ;
Talhouk, Aline ;
Sherman, Mark E. ;
Wentzensen, Nicolas .
CLINICAL CANCER RESEARCH, 2019, 25 (19) :5937-5946
[24]   Is Routine Nodal Dissection in Early Epithelial Ovarian Cancers Required? [J].
Agarwal, Arjun ;
Hemanth, G. N. ;
Garg, Cheena ;
Ganesh, M. S. ;
Keerthi, B. R. ;
Prabha, Amritha ;
Abhinay, I. .
INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 18 (03)
[25]   A Translational Model to Improve Early Detection of Epithelial Ovarian Cancers [J].
Gockley, Allison ;
Pagacz, Konrad ;
Fiascone, Stephen ;
Stawiski, Konrad ;
Holub, Nicole ;
Hasselblatt, Kathleen ;
Cramer, Daniel W. ;
Fendler, Wojciech ;
Chowdhury, Dipanjan ;
Elias, Kevin M. .
FRONTIERS IN ONCOLOGY, 2022, 12
[26]   Treatment planning of epithelial ovarian cancers using helical tomotherapy [J].
Jamema, Swamidas V. ;
Mahantshetty, Umesh ;
Goel, Vineeta ;
Engineer, Reena ;
Deshpande, Deepak D. ;
Sarin, Rajiv ;
Shrivastava, Shyam Kishore .
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2009, 10 (04) :96-105
[27]   Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers [J].
Han, Jasmine J. ;
Yu, Minshu ;
Houston, Nicole ;
Steinberg, Seth M. ;
Kohn, Elise C. .
GYNECOLOGIC ONCOLOGY, 2011, 120 (01) :5-10
[28]   Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers [J].
Azzalini, Eros ;
Stanta, Giorgio ;
Canzonieri, Vincenzo ;
Bonin, Serena .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (20)
[29]   Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers [J].
Lee, Yoo-Kyung ;
Park, Noh-Hyun ;
Lee, Hyunsook .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2015, 47 :e195-e195
[30]   Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors [J].
Arias-Pulido, Hugo ;
Smith, Harriet O. ;
Joste, Nancy E. ;
Bocklage, Therese ;
Qualls, Clifford R. ;
Chavez, Allison ;
Prossnitz, Eric R. ;
Verschraegen, Claire F. .
GYNECOLOGIC ONCOLOGY, 2009, 114 (03) :480-485